Edgewise Therapeutics Inc

While the medium-term structure remains bullish with a Stage 2 advance and a recent momentum breakout above consolidation, short-term exhaustion at the highs and extended price above EMAs suggest timing is poor. Execution is best deferred to a pullback into the rising EMAs and 50 SMA for an asymmetric entry.

• ↑Sale of muscular dystrophy unit raised $1.55B capital
• ↑Pro forma cash balance ~$2.01B bolsters R&D funding
• ↓Low profitability score highlights ongoing earnings struggles